January 2026 Research Update

This month added two pieces to the same picture: behavior questionnaires in Rett syndrome can be useful for tracking symptoms, but they have limits and need careful interpretation. A large Australian dataset showed that behavior and emotional symptom scores can shift over years and tend to improve modestly with age for many people, while also showing clear differences between subgroups. A separate Korean translation study showed that bringing these tools into new languages is feasible, but agreement between different raters can be a challenge, which matters when families and professionals both fill out forms. [1] [2]

In the Australian Rett Syndrome Database, researchers found three general patterns of Rett Syndrome Behaviour Questionnaire (RSBQ) scores: low, middle, and high symptom groups, with scores declining modestly with age. Mobility and nutrition-related status stood out more clearly than genotype or seizure frequency, with independent walking and higher weight linked to lower symptom-score trajectories. This helps describe what kinds of symptom paths are commonly seen in routine life, not just in short studies. [1]

In Korea, researchers translated the RSBQ and tested the Korean version with 66 primary caregivers, finding strong internal consistency and moderate stability when the same person repeated the questionnaire. Agreement between different raters was generally low, meaning two people rating the same individual could score symptoms differently. This kind of work supports international research and care tracking, but also shows that more validation is needed before results are treated as interchangeable across raters or settings. [2]

For families, these studies reinforce that symptom questionnaires can capture meaningful patterns over time, including that some behavioral and emotional symptoms may lessen with age in many individuals. They also highlight that questionnaire scores can depend on who fills them out, especially in translated versions, which can make day-to-day comparisons harder unless the same rater is used. This mainly adds understanding and better tools for future studies and long-term tracking, rather than changing treatment choices by itself. [1] [2]

Two large natural history analyses this month helped clarify a practical point about Rett syndrome: many skills are gained early, and when skills are lost it often happens relatively soon after they were gained, while later regains are less common. At the same time, long-term behavior questionnaires showed that some behavior and mood-related symptoms can improve modestly with age, even while other challenges persist. Taken together, these studies describe a condition where different parts of functioning can move in different directions across childhood and adulthood. [3] [1]

In the US Rett Natural History Study, researchers tracked 51 developmental skills in 1,228 females with classic Rett syndrome and MECP2 variants. Most skills were acquired by early childhood, and skill loss often happened within 2 years of gaining that skill, especially for fine motor and expressive language. Regaining a lost skill was reported, but it was uncommon and usually occurred before age 6. [3]

The Australian behavior-trajectory work complements this by focusing on behavioral and emotional symptoms rather than milestones. RSBQ total scores declined modestly with age, and the group with the highest scores showed a decline after age 20. These trends help set expectations for what kinds of changes researchers might detect over years in observational follow-up. [1]

For patients and caregivers, these results mainly help put changes into a timeline: the window for gaining new developmental skills is usually early, and skill loss often follows within a few years, while later regains are less commonly reported. Separately, some aspects of behavior and mood may ease modestly with age for many people, based on long-term questionnaire data. This does not predict what will happen to any one person, but it provides a clearer shared reference point for conversations and for designing future studies that measure meaningful change. [3] [1]

This month brought two kinds of real-world health information that families often ask about: what side effects get reported after starting trofinetide, and whether people with Rett syndrome can build antibody responses after COVID-19 vaccination. The trofinetide analysis highlighted that reported side effects were mostly stomach and gut-related and often appeared early after starting. The vaccine study, although small, found immune responses that looked similar to healthy controls, suggesting no obvious signal of a weaker antibody and memory B cell response in that group. [4] [5]

In a US adverse event reporting database analysis, trofinetide reports most often involved gastrointestinal problems, with diarrhea described as a prominent signal. The study also noted reports of decreased appetite, weight loss, and irritability, and many reported events happened within 0 to 30 days of starting treatment. Because this was based on spontaneous reports, it can highlight patterns to watch but cannot prove the drug caused any specific event. [4]

In a prospective study of 23 females with Rett syndrome compared with 23 healthy controls, researchers measured antibodies and memory B cells after 2 or 3 doses of an mRNA COVID-19 vaccine. Rett syndrome participants had spike-specific antibodies, functional reactivity, and memory B cell findings that were broadly comparable to controls, with higher responses seen in those who had also been infected. The study did not focus on clinical protection, but it adds human data showing that people with Rett syndrome in this small group were able to develop measurable antibody and memory B-cell responses after vaccination. [5]

For families considering how research findings relate to everyday health, these studies add information but in different ways. The trofinetide report analysis may matter now by clarifying what types of side effects were most often reported in routine use, especially early after starting, while still leaving uncertainty about how common these events truly are. The vaccine study mainly adds reassurance at the research level that antibody and memory B cell responses can look similar to peers in a small group with Rett syndrome, but larger studies would be needed to confirm this across ages and health situations. [4] [5]

Several studies this month focused on mechanisms in animals and laboratory systems, aiming to explain why certain symptoms might happen in Rett syndrome. Across these projects, a shared message is that MeCP2 changes can alter brain signaling in specific circuits and may affect how the body processes sensory signals like pain. Another study expanded the view of what MeCP2 can bind to in the nucleus, suggesting it may interact with chemical marks on histones (proteins that package DNA) in addition to DNA itself. [6] [7] [8]

In Mecp2 heterozygous female mice, pain sensitivity changed with age, shifting from higher sensitivity before obvious symptoms to lower apparent sensitivity as motor symptoms emerged. The researchers also saw lower activation and lower CB1 receptor expression in a brain region involved in pain control in older mice. This suggests that, at least in this model, movement changes and altered internal pain control systems could both shape how pain responses look over time. [6]

In another mouse study targeting MeCP2 loss in a specific type of inhibitory neuron, researchers found weaker inhibitory signaling in the amygdala and reduced connectivity across a broader amygdala-hippocampus-prefrontal network. The work points to a circuit-level explanation for how changes in inhibitory neurons could raise excitability in key emotion-related brain regions. It does not directly test symptoms in people, but it helps map where and how brain signaling may be altered. [7]

In cell and biochemical experiments, researchers identified a binding pocket in MeCP2 that recognized certain histone methylation marks, including H3K27me3, and showed that specific mutations reduced this binding and altered chromatin localization and target gene regulation. They proposed that MeCP2 may act as a reader of histone marks, not only as a DNA methylation-binding protein. This expands the basic biology picture of MeCP2 function, though it was not tested in neurons or in living patients. [8]

For patients and caregivers, these studies are early-stage and mainly shape the longer-term research roadmap rather than immediate care. They help clarify that Rett-related changes can affect specific brain circuits and may influence how sensory signals like pain are processed over time, at least in mouse models. They also suggest that MeCP2 may influence gene activity through more than one type of chromatin binding, which could matter for future therapy ideas. What remains uncertain is how directly these lab findings translate to the day-to-day experiences of people with Rett syndrome and which mechanisms are most important in humans. [6] [7] [8]

A single case report this month highlighted how Rett syndrome can be diagnosed through broad genetic testing even when the presentation is not typical. The central point was that whole exome sequencing helped reach a diagnosis in a child without the expected regression history. As one case, it does not show how often this happens, but it illustrates a pathway some families experience in real life. [9]

The report described an outpatient neurodevelopmental genetics program that used a multidisciplinary approach and consent processes that did not rely only on genetics providers. The authors emphasized that this approach enabled access to resources and support after the diagnosis was made. This is descriptive information rather than a test of outcomes. [9]

For families, this case mainly adds a reminder that genetic testing pathways can differ, and some children may receive a Rett diagnosis even with an atypical early history. It may matter now in the sense that it normalizes varied diagnostic journeys, but it does not establish which testing strategy is best or most available. The uncertainty is that a single report cannot show how often similar cases occur or whether this clinic approach improves long-term outcomes. [9]